Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old, male or female.
• People whose general health and ability to function meets a minimum standard score (called Karnofsky Performance Status Score ≥70), meaning they are able to carry out normal activity with only minor symptoms (confirm with trial site).
• People who have been diagnosed with a type of stomach cancer called gastric adenocarcinoma that tests negative for a protein called HER2.
• People whose stomach cancer is either too advanced to be removed by surgery right away, or is potentially removable and has spread in a limited way — for example, to a single spot on the liver, to certain nearby lymph nodes, or where cancer cells have been found floating in the abdominal cavity.
• People whose overall physical health and organ function are considered suitable for major abdominal surgery.
• People whose blood test results meet specific minimum levels for red blood cells, white blood cells, platelets, liver function, kidney function, and protein levels in the blood (confirm exact values with trial site).
• People whose heart pumping function, measured by an ultrasound of the heart, shows the heart is working at 50% or better.
• People who do not have another serious illness that is expected to shorten their life to less than 5 years.
• People who are willing and able to follow the trial's procedures throughout the study period.
• People who have given written consent before the trial begins, and have been informed that leaving the trial at any time is allowed without any negative consequences.

Who may not be able to join:

• People who have already received chemotherapy, radiation therapy, or immunotherapy as treatment for their stomach cancer (steroid treatments are an exception).
• People who are pregnant or currently breastfeeding.
• Women of childbearing age whose pregnancy test at the start of the trial is positive, or who have not had a pregnancy test. Women who have gone through menopause must have had no periods for at least 12 months to be considered unable to become pregnant.
• Men and women who are able to have children but are unwilling to use contraception during the study.
• People who have fluid build-up in the abdomen (ascites) as well as cancer cells found floating in the abdominal cavity at the same time.
• People who have had another type of cancer in the past 5 years, except for certain skin cancers that have been fully cured or a very early-stage cervical condition that has been treated.
• People with a history of epilepsy, brain or nervous system conditions, or mental health disorders that the trial doctor believes could affect their ability to give informed consent or take oral medication reliably.
• People with significant active heart problems, such as symptomatic coronary heart disease, moderate-to-severe heart failure, serious heart rhythm problems caused by medication, or a heart attack within the past 12 months.
• People with conditions affecting the upper digestive system that may prevent proper absorption of one of the study medications (called S-1).
• People with existing nerve damage in the hands or feet rated at a moderate level or above (NCI CTC AE grade 2 or higher), unless the only finding is loss of a specific reflex with no other symptoms (confirm with trial site).
• People who have had an organ transplant and require medication to suppress their immune system.
• People with severe infections that cannot be controlled, or other serious uncontrolled health conditions.
• People with moderate or severe kidney impairment, based on a kidney function calculation (creatinine clearance at or below 50ml/min) or abnormal blood creatinine levels.
• People known to have a specific enzyme deficiency called DPD (dihydropyrimidine dehydrogenase deficiency), which affects how certain cancer medicines are broken down by the body.
• People who have a known allergy to a class of cancer medicines called taxanes, or to any ingredient used in the trial treatments.
• People who have taken part in another clinical trial or received an experimental treatment within the 4 weeks before joining this trial.

Important: Always verify eligibility with the trial site directly before applying.